Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2011

View Archived Issues

Volasertib is active as second-line therapy for urothelial cancer in phase II trial

Trophos completes dose-escalating phase I trial of TRO-40303

BioCryst receives additional funding from U.S. government for phase III development of peramivir

Ipsen and bioMerieux partner for personalized cancer medicine

FDA refuses to file Rhucin BLA

FDA approves Takeda's Edarbi to treat high blood pressure

Kuros begins treating patients in pilot study of dural sealant KUR-023

TAK-733 has potent antitumor activity in vivo

Drug-activated dendritic cell vaccine BPX-101 leads to antigen-specific immunity in mCRPC

Therapy based on vitamin D shows promise in model of prostate cancer

GSK receives full FDA approval for Promacta in chronic ITP

FDA grants priority review for Istodax sNDA in peripheral T-cell lymphoma

Shire files complete response to FDA's not approvable letter for Firazyr

Novel acyl-CoA desaturase inhibitors discovered at Pierre Fabre

New inhibitors of tyrosine-protein kinase JAK enzymes claimed

TB Alliance discovers new agents for tuberculosis

New 11-beta-HSD1 inhibitors patented at sanofi-aventis

New glucokinase activators reported by Zydus-Cadila

Phase I study evaluates KP-201 as abuse-deterring agent for pain

FDA requests more data for Protalix's taliglucerase alfa NDA

Seattle Genetics submits BLA for brentuximab in Hodgkin's and large cell lymphoma

Epigenomics and Qiagen collaborate on blood test for colorectal cancer

FDA approves Intuniv as adjunctive treatment to stimulants for ADHD

Phase II data reported on cariprazine as adjunctive therapy in MDD

Novavax licenses VLP technology to LG Life Sciences for South Korea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...